# Compare BPC-157, KLOW, KPV, and TB-500 — Peptide R Lab

> A side-by-side comparison of four Recovery & Tissue Repair research peptides — BPC-157, KLOW, KPV, and TB-500 — across mechanism, most-studied application, human evidence base, regulatory status, and key caution.

How BPC-157, KLOW, KPV, and TB-500 differ in mechanism, human evidence, regulatory status, and the one caution that matters most for each.

## The short version

This page lines up [BPC-157](/bpc-157), [KLOW](/klow), [KPV](/kpv), and [TB-500](/tb-500) on the dimensions that matter most when reading tissue-repair peptide research: mechanism, most-studied application, human evidence base, regulatory and anti-doping status, and the single most important caution for each. The honest headline: three of the four (BPC-157, KPV, TB-500) are individual research peptides with human evidence ranging from a two-person safety pilot to zero human trials at all, and the fourth (KLOW) is a combination product that has never been tested as a combination. None of the four is FDA-approved, one (TB-500, and by extension KLOW, which contains it) is WADA-prohibited, and no human dose is recommended anywhere on this notebook.

## The comparison matrix

| Dimension | BPC-157 | KLOW | KPV | TB-500 |
| --- | --- | --- | --- | --- |
| Molecular class | 15-amino-acid pentadecapeptide, gastric-protein derived | 4-peptide co-formulated research vial (not a single molecule) | 3-amino-acid tripeptide, C-terminal fragment of alpha-MSH | 7-amino-acid synthetic fragment (Ac-LKKTETQ) of thymosin beta-4 |
| Proposed mechanism | VEGFR2-Akt-eNOS angiogenesis; FAK-paxillin migration [4] | Combines BPC-157 angiogenesis + TB-500 actin/migration + KPV NF-kB suppression + GHK-Cu matrix synthesis (untested as a stack) | PepT1-mediated uptake; NF-kB/MAPK suppression [9] | G-actin sequestration and cell migration (fragment carries the motif; most data are on the full protein) [17] |
| Most-studied in | Gastric ulcer healing, tendon/ligament, gut mucosa (rodent) | Not studied as a blend; components studied individually | Murine colitis / gut-inflammation models | Wound healing, cardiac repair, stroke (chiefly full-length Tβ4) |
| Human evidence | One IV safety pilot, n=2 [1] | None; zero blend-specific human data | None; zero human trials of any kind | One Phase 1 safety trial, n=40 (full-length protein) [16] |
| Regulatory / anti-doping status | Not approved; FDA flagged as ineligible for 503A compounding pending review | Not approved; contains TB-500, a WADA-prohibited component | Not approved; no specific WADA listing | Not approved; WADA-prohibited at all times (S2 category) [6] |
| Key caution | Human evidence is extremely thin; largely single-research-group literature [1][2] | The four-peptide combination itself has never been tested; built-in pharmacokinetic mismatch [3][16] | Zero human trials of any kind; the entire literature is preclinical [9][10][11][12] | Fragment-vs-full-protein identity confusion; no completed human trial of the fragment itself [15][16] |

## Mechanism: three different repair levers

BPC-157, KPV, and TB-500 sit at three largely separate nodes of the same repair cascade. BPC-157's best-documented route is angiogenesis, up-regulating VEGFR2 and driving VEGFR2-Akt-eNOS signaling to build new blood vessels and speed blood flow to injured tissue [4]. TB-500's actin-binding fragment is proposed to work through cell mobility instead, sequestering G-actin to free up the cytoskeletal machinery cells need to migrate toward a wound [17]. KPV works upstream of both, damping the NF-kB and MAP-kinase inflammatory signaling that would otherwise keep a wound in an inflamed state [9]. KLOW packages all three of these levers into one vial, plus a fourth ingredient (GHK-Cu, not covered as its own entry here) that acts at the gene-expression level to drive matrix synthesis. The combination logic is coherent on paper, angiogenesis, motility, and inflammation control addressed together, but no study has confirmed the levers actually work better pulled at once.

## Most-studied application

BPC-157's literature centers on gastric-ulcer healing and, more recently, tendon and ligament repair and gut-mucosal protection, almost entirely in rats [4][5]. TB-500's literature, again chiefly using the full-length parent protein, centers on dermal wound healing, corneal injury, cardiac repair after ischemia, and, in one dose-response study, post-stroke neurological recovery in rats [14][18][19]. KPV's literature is narrower and more consistent: essentially every study is a mouse model of colitis or gut-mucosal inflammation [9][10][11][12]. KLOW has no dedicated application literature of its own; vendors market it broadly for recovery, skin, and gut complaints, borrowing the application areas of its four separate ingredients.

## Human evidence base

This is where the four genuinely separate. BPC-157 has exactly one human data point: a 2025 pilot giving two healthy adults an intravenous dose with no adverse findings [1], informative about tolerability, uninformative about efficacy. TB-500's parent protein has a real Phase 1 safety trial in 40 volunteers [16], but that trial used full-length thymosin beta-4, not the fragment sold as TB-500, so even this comparatively better human record does not directly cover the product on shelves. KPV has zero human studies of any kind; its entire evidence base is in vitro and mouse colitis work [9][10][11][12]. KLOW, as a blend, has zero blend-specific studies at any phase; its 'evidence' is entirely inherited from its four separate ingredients. Ranked from least to most human evidence: KPV and KLOW tie at none, BPC-157 has a two-person pilot, and TB-500's parent protein has the field's only real Phase 1 trial.

## Regulatory and anti-doping status

None of the four is FDA-approved for human use. BPC-157 was placed by the FDA into a category of substances found ineligible for 503A pharmacy compounding pending further evaluation. TB-500 (thymosin beta-4) is explicitly prohibited by the World Anti-Doping Agency at all times, under its peptide hormone / growth factor category, with anti-doping labs having developed methods to detect it [6]. KPV carries no specific WADA classification, though as an unapproved peptide it should be treated cautiously in any tested-athlete context. KLOW inherits the strictest status of its ingredients: because it contains TB-500, using KLOW implicates the same anti-doping rules as using TB-500 alone, regardless of intent.

## Key caution

Each entry carries a defining caveat. For BPC-157, it is the sheer thinness of the human record combined with a literature concentrated in one research group [1][2]. For KLOW, it is that the four-peptide combination has never itself been tested, paired with a genuine pharmacokinetic mismatch between its fast-clearing tripeptides and its longer-acting components [3][16]. For KPV, it is the complete absence of human data; every finding here is preclinical [9][10][11][12]. For TB-500, it is the identity gap between the well-studied full-length protein and the fragment actually sold under that name, which has no completed human trial of its own [15][16]. Read together, the pattern across all four is consistent: promising animal-model mechanisms, a research-only regulatory status, and a human evidence base that ranges from thin to nonexistent.

---

Peptide R Lab keeps a citation-anchored bench log on tissue-repair peptides — a research chart, not a treatment plan.